Sunshine Biopharma files $4 million at-the-market stock offering with Aegis Capital

Sunshine Biopharma Inc. filed a prospectus supplement dated July 20, 2026 covering an at-the-market offering of up to $4,000,000 in common stock. The company entered into an At-The-Market Issuance Sales Agreement with Aegis Capital Corp., which will act as exclusive sales agent.¹

Sunshine will pay Aegis a fixed cash commission equal to 3.0% of gross proceeds from each sale of stock sold under the agreement.¹ The company also agreed to reimburse Aegis for legal and out-of-pocket expenses of $75,000, plus $2,500 following each Form 10-Q filing and $7,500 following each annual report on Form 10-K.¹ Total offering expenses, excluding compensation and reimbursements to Aegis, are estimated at approximately $100,000.¹

The common stock trades on the Nasdaq Capital Market under the symbol "SBFM," and closed at $1.80 per share on July 17, 2026.¹ The company noted that prior to a 10-for-1 reverse stock split effective June 1, 2026, its stock had recently traded below Nasdaq's $1.00 minimum bid price requirement, and it remains subject until June 2027 to an immediate delisting notice if it falls out of compliance for 30 consecutive business days, given the recent reverse split.¹

Sunshine intends to use net proceeds from the offering for general corporate purposes, including working capital.¹ The company describes itself as a pharmaceutical business researching medicines in oncology and antivirals, with two wholly owned subsidiaries: Nora Pharma Inc., which markets 60 generic prescription drugs in Canada, and Sunshine Biopharma Canada Inc., which sells OTC supplements.¹ It is also developing K1.1 mRNA, a liver-cancer-targeted mRNA candidate, and SBFM-PL4, a protease inhibitor aimed at SARS Coronavirus infections.¹